Retinalamin

Retinalamin is a polypeptide preparation isolated from bovine retinal tissue, developed by Professor Vladimir Khavinson and registered as a pharmaceutical drug in Russia for the treatment of retinal degenerative diseases. It is studied for age-related macular degeneration (AMD), retinitis pigmentosa, and diabetic retinopathy, and is the primary ocular bioregulator in the Khavinson peptide system.

Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight below 10,000 Da, isolated from bovine retina by Khavinson's extraction method. It activates ocular tissue metabolism, normalizes cellular membrane function, improves intracellular protein synthesis, and regulates lipid peroxide oxidation in photoreceptor and pigment epithelial cells. By improving the functional interaction between the retinal pigment epithelium (RPE) and the outer segments of visual photoreceptors, it helps restore phototransduction efficiency. It also normalizes retinal vascular permeability, reducing macular edema. The preparation penetrates retinal layers after intramuscular injection, exerting tissue-specific bioregulatory effects on photoreceptor renewal and RPE metabolic activity.

Russian clinical studies involving Retinalamin in AMD, retinitis pigmentosa, and diabetic retinopathy report visual function improvement in up to 80% of treated patients across observational series. A study combining Retinalamin with Epithalamin and Cortexin in 104 diabetic retinopathy patients showed improved visual acuity and reduced macular edema. Long-term outcome data in retinal degenerative disorders is published in Russian ophthalmology journals. No randomized controlled trials meeting FDA standards have been published in Western peer-reviewed literature. Retinalamin is registered and approved in Russia as a retinoprotective pharmaceutical.

Peptides commonly paired with Retinalamin for synergistic effects.